No Data
No Data
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) price-to-earnings (or "P/E") ratio of 18.7x might make it look like a buy right now compared to the market in China, where around half of the
Sichuan Kelun Pharmaceutical (002422.SZ): The sales revenue of 0.034 billion yuan for the company's Dapoxetine hydrochloride in 2023.
On July 11th, Gelunhui reported that Sichuan Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform that the sales revenue of dapoxetine hydrochloride will be 0.034 billion yuan in 2023.
Kelun-Biotech to Buy Equipment From Sichuan Kelun Pharmaceutical's Unit
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will purchase certain equipment from Chengdu Kelun Precision Biotechnology, a unit of Sichuan Kelun Pharmaceutical (SHE:002422), for a little over 6.
Kelun Biotech-B (06990) plans to acquire a series of equipment from its subsidiary of Sichuan Kelun Pharmaceutical (002422.SZ) for 6.24 million yuan.
Kelun Biotech-B (06990) announced on June 28, 2024 that the company had signed a cooperation agreement with Sichuan Kelun Pharmaceutical (0...
Is There An Opportunity With Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) 50% Undervaluation?
Key Insights The projected fair value for Sichuan Kelun Pharmaceutical is CN¥61.60 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥31.08 suggests Sichuan Kelun Pharmaceutical is
Sichuan Kelun Pharmaceutical (002422.SZ): Subsidiary's application for clinical trial of new drug SKB518 for injection of innovative drugs approved.
On June 17th, Gelunhui reported that Sichuan Kelun Biomedical Pharmaceutical Co., Ltd. (hereafter referred to as "Kelun Biomedical"), a subsidiary controlled by Kelun Pharmaceutical, recently received a clinical trial notice for the innovative drug injection SKB518, which was approved by the National Medical Products Administration (NMPA) Drug Evaluation Center. Injection SKB518 is a innovative antibody developed by Kelun Biomedical using the "OptiDCTM" platform technology based on the biological characteristics of the target. It has independent intellectual property rights.
No Data